Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Comparative evolutionary and structural bioinformatic analysis of the human N-Acetyltransferase-2 (NAT2) gene with different mammalian and avian taxa.
Khan N et al.
Bmc Genomics, 2026
Pharmacogenomics and mutation informatics: correlation of NAT2 mutations and isoniazid acetylation rate.
Verma S et al.
Drug Discovery Today, 2026
PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.
Papanikolaou G et al.
Clinical Pharmacology and Therapeutics, 2025
Pharmacogenomic heterogeneity of N-acetyltransferase 2: a comprehensive analysis of real world data in Indian tuberculosis patients and from literature and database review.
Thomas L et al.
Annals of Medicine, 2025
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort.
Schiuma M et al.
International Journal of Molecular Sciences, 2025
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
The impact of genetic variability on Alzheimer's therapies: obstacles for pharmacogenetic progress.
Cacabelos R et al.
Expert Opinion on Drug Metabolism & Toxicology, 2025
Drug-induced hepatotoxicity and association with slow acetylation variants NAT2*5 and NAT2*6 in Cameroonian patients with tuberculosis and HIV co-infection.
Cho FN et al.
Bmc Infectious Diseases, 2024
Determination of NAT2 Genotypes in a Cohort of Patients with Suspected TB in the State of Rio de Janeiro.
Dutra CA et al.
Pharmaceutics, 2024
Function and expression of N-acetyltransferases 1 and 2 are altered in lymphocytes in type 2 diabetes and obesity.
Paz-Rodríguez VA et al.
Biochemistry and Biophysics Reports, 2024
A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2024
Pharmacogenetic variability of tuberculosis biomarkers in native and mestizo Peruvian populations.
Jaramillo-Valverde L et al.
Pharmacology Research & Perspectives, 2024
Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients.
Thomas L et al.
Expert Review of Clinical Pharmacology, 2024
Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity.
Yoon JG et al.
Experimental & Molecular Medicine, 2024
Towards pharmacogenomics-guided tuberculosis (TB) therapy: N-acetyltransferase-2 genotypes among TB-infected Kenyans of mixed ethnicity.
Njagi LN et al.
Bmc Medical Genomics, 2024
Direct Comparative Analysis of a Pharmacogenomics Panel with PacBio Hifi® Long-Read and Illumina Short-Read Sequencing.
Barthélémy D et al.
Journal of Personalized Medicine, 2023
The effect of the rs1799931 G857A (G286E) polymorphism on N-acetyltransferase 2-mediated carcinogen metabolism and genotoxicity differs with heterocyclic amine exposure.
Hein DW et al.
Archives of Toxicology, 2023
A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
Verma R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
Pharmacogenetics of anxiety and depression in Alzheimer's disease.
Cacabelos R et al.
Pharmacogenomics, 2023
N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study.
Cheng F et al.
Frontiers in Pharmacology, 2023
Clinical Significance of NAT2 Genetic Variations in Type II Diabetes Mellitus and Lipid Regulation.
Jarrar Y et al.
Pharmacogenomics and Personalized Medicine, 2023
Human N-acetyltransferase 2 (NAT2) gene variability in Brazilian populations from different geographical areas.
Lopes MQP et al.
Frontiers in Pharmacology, 2023
Genetic susceptibility of bladder cancer in the Lebanese population.
Kourie HR et al.
Bmc Medical Genomics, 2022
Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy.
Khan A et al.
Global Medical Genetics, 2022
Gene Polymorphism of Biotransformation Enzymes and Ciprofloxacin Pharmacokinetics in Pediatric Patients with Cystic Fibrosis.
Zyryanov SK et al.
Biomedicines, 2022
Homozygotes NAT2*5B slow acetylators are highly associated with hepatotoxicity induced by anti-tuberculosis drugs.
El-Jaick KB et al.
Memorias Do Instituto Oswaldo Cruz, 2022
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing.
Silgado-Guzmán DF et al.
Frontiers in Pharmacology, 2022
Sulfamethoxazole-trimethoprim-induced liver injury and genetic polymorphisms of NAT2 and CYP2C9 in Taiwan.
Huang YS et al.
Pharmacogenetics and Genomics, 2021
A Rapid Pharmacogenomic Assay to Detect NAT2 Polymorphisms and Guide Isoniazid Dosing for Tuberculosis Treatment.
Verma R et al.
American Journal of Respiratory and Critical Care Medicine, 2021
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.
Ramirez J et al.
British Journal of Clinical Pharmacology, 2021
Allelic and genotypic frequencies of NAT2, CYP2E1, and AADAC genes in a cohort of Peruvian tuberculosis patients.
Levano KS et al.
Molecular Genetics & Genomic Medicine, 2021
Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.
Nakai T et al.
Bmc Medical Genomics, 2021
Arylamine N-acetyltransferase acetylation polymorphisms: paradigm for pharmacogenomic-guided therapy- a focused review.
Hein DW et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
Association Between NAT2 Polymorphism and Lung Cancer Risk: A Systematic Review and Meta-Analysis.
Zhu K et al.
Frontiers in Oncology, 2021
Defining eligible patients for allele-selective chemotherapies targeting NAT2 in colorectal cancer.
Rendo V et al.
Scientific Reports, 2020
Phenotype prediction and characterization of 25 pharmacogenes in Thais from whole genome sequencing for clinical implementation.
Mauleekoonphairoj J et al.
Scientific Reports, 2020
Inherited Genetic Mutations and Polymorphisms in Malignant Mesothelioma: A Comprehensive Review.
Panou V et al.
International Journal of Molecular Sciences, 2020
N-Acetyltransferase 2 Genotypes among Zulu-Speaking South Africans and Isoniazid and N-Acetyl-Isoniazid Pharmacokinetics during Antituberculosis Treatment.
Mthiyane T et al.
Antimicrobial Agents and Chemotherapy, 2020
Study on Genotyping Polymorphism and Sequencing of N-Acetyltransferase 2 (NAT2) among Al-Ahsa Population.
Zahra MA et al.
Biomed Research International, 2020
Genotype-Guided Hydralazine Therapy.
Collins KS et al.
American Journal of Nephrology, 2020
Genotype-Environment Interaction Analysis of NQO1, CYP2E1, and NAT2 Polymorphisms and the Risk of Childhood Acute Lymphoblastic Leukemia: A Report From the Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia.
Medina-Sanson A et al.
Frontiers in Oncology, 2020
Genomewide Association Study Confirming the Association of NAT2 with Susceptibility to Antituberculosis Drug-Induced Liver Injury in Thai Patients.
Suvichapanich S et al.
Antimicrobial Agents and Chemotherapy, 2019
N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.
Kotila OA et al.
Pharmacogenetics and Genomics, 2019
Sequence analysis of the N-acetyltransferase 2 gene (NAT2) among Jordanian volunteers.
Jarrar YB et al.
The Libyan Journal of Medicine, 2018
Expression and genotype-dependent catalytic activity of N-acetyltransferase 2 (NAT2) in human peripheral blood mononuclear cells and its modulation by Sirtuin 1.
Salazar-González RA et al.
Biochemical Pharmacology, 2018
Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
Hernández-González O et al.
Leukemia & Lymphoma, 2018
Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis.
Dompreh A et al.
Antimicrobial Agents and Chemotherapy, 2018